Tonghua Dongbao Pharmaceutical Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Tonghua Dongbao Pharmaceutical is forecast to grow earnings and revenue by 69.4% and 24.4% per annum respectively. EPS is expected to grow by 71.2% per annum. Return on equity is forecast to be 15.4% in 3 years.
Anahtar bilgiler
69.4%
Kazanç büyüme oranı
71.2%
EPS büyüme oranı
Pharmaceuticals kazanç büyümesi | 19.3% |
Gelir büyüme oranı | 24.4% |
Gelecekteki özkaynak getirisi | 15.4% |
Analist kapsamı | Good |
Son güncelleme | 04 Nov 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Pretty Healthy Balance Sheet
Oct 22Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Earnings Haven't Escaped The Attention Of Investors
Sep 30Some May Be Optimistic About Tonghua Dongbao Pharmaceutical's (SHSE:600867) Earnings
Sep 06Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Analysts Just Slashed This Year's Estimates
Sep 05Calculating The Intrinsic Value Of Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867)
Aug 22Tonghua Dongbao Pharmaceutical (SHSE:600867) Has A Rock Solid Balance Sheet
Jun 19Improved Earnings Required Before Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Shares Find Their Feet
May 23Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 3,907 | 1,320 | N/A | 1,317 | 5 |
12/31/2025 | 3,235 | 1,055 | N/A | 1,088 | 6 |
12/31/2024 | 2,148 | 88 | N/A | 1,013 | 3 |
9/30/2024 | 2,432 | 341 | 75 | 614 | N/A |
6/30/2024 | 2,449 | 453 | 227 | 667 | N/A |
3/31/2024 | 3,001 | 1,132 | 524 | 858 | N/A |
12/31/2023 | 3,075 | 1,168 | 513 | 862 | N/A |
9/30/2023 | 2,771 | 939 | 130 | 528 | N/A |
6/30/2023 | 2,757 | 884 | 213 | 611 | N/A |
3/31/2023 | 2,556 | 1,001 | 213 | 666 | N/A |
12/31/2022 | 2,778 | 1,582 | 370 | 863 | N/A |
9/30/2022 | 2,912 | 1,643 | 565 | 1,185 | N/A |
6/30/2022 | 2,993 | 1,820 | 405 | 1,160 | N/A |
3/31/2022 | 3,332 | 1,803 | 476 | 1,163 | N/A |
12/31/2021 | 3,268 | 1,308 | 580 | 1,180 | N/A |
9/30/2021 | 3,162 | 1,242 | 654 | 1,147 | N/A |
6/30/2021 | 3,079 | 1,060 | 849 | 1,188 | N/A |
3/31/2021 | 2,996 | 989 | 854 | 1,206 | N/A |
12/31/2020 | 2,892 | 930 | 713 | 1,192 | N/A |
9/30/2020 | 2,906 | 879 | 658 | 1,054 | N/A |
6/30/2020 | 2,817 | 820 | 794 | 1,174 | N/A |
3/31/2020 | 2,781 | 815 | 856 | 1,119 | N/A |
12/31/2019 | 2,777 | 811 | 859 | 1,152 | N/A |
9/30/2019 | 2,741 | 839 | 787 | 1,109 | N/A |
6/30/2019 | 2,664 | 834 | 477 | 1,001 | N/A |
3/31/2019 | 2,688 | 838 | 139 | 1,099 | N/A |
12/31/2018 | 2,693 | 839 | 104 | 877 | N/A |
9/30/2018 | 2,701 | 876 | 263 | 938 | N/A |
6/30/2018 | 2,827 | 963 | N/A | 954 | N/A |
3/31/2018 | 2,699 | 900 | N/A | 898 | N/A |
12/31/2017 | 2,545 | 837 | N/A | 961 | N/A |
9/30/2017 | 2,414 | 789 | N/A | 900 | N/A |
6/30/2017 | 2,332 | 736 | N/A | 818 | N/A |
3/31/2017 | 2,154 | 690 | N/A | 840 | N/A |
12/31/2016 | 2,040 | 641 | N/A | 726 | N/A |
9/30/2016 | 1,909 | 604 | N/A | 687 | N/A |
6/30/2016 | 1,779 | 546 | N/A | 577 | N/A |
3/31/2016 | 1,722 | 533 | N/A | 359 | N/A |
12/31/2015 | 1,669 | 493 | N/A | 295 | N/A |
9/30/2015 | 1,661 | 450 | N/A | 248 | N/A |
6/30/2015 | 1,576 | 393 | N/A | 105 | N/A |
3/31/2015 | 1,521 | 321 | N/A | 158 | N/A |
12/31/2014 | 1,451 | 280 | N/A | 206 | N/A |
9/30/2014 | 1,369 | 215 | N/A | 142 | N/A |
6/30/2014 | 1,308 | 216 | N/A | 285 | N/A |
3/31/2014 | 1,265 | 198 | N/A | 305 | N/A |
12/31/2013 | 1,204 | 184 | N/A | 221 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 600867's forecast earnings growth (69.4% per year) is above the savings rate (2.9%).
Kazançlar ve Piyasa: 600867's earnings (69.4% per year) are forecast to grow faster than the CN market (25.8% per year).
Yüksek Büyüme Kazançları: 600867's earnings are expected to grow significantly over the next 3 years.
Gelir ve Pazar: 600867's revenue (24.4% per year) is forecast to grow faster than the CN market (14% per year).
Yüksek Büyüme Geliri: 600867's revenue (24.4% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 600867's Return on Equity is forecast to be low in 3 years time (15.4%).